乳脂肪球表面生长因子8、糖类抗原153和癌胚抗原在乳腺癌中的表达及意义

Expression and significance of milk fat globule epidermal growth factor 8 and carbohydrate antigen 153, carcinoembryonic antigen in breast cancer

目的 探讨乳脂肪球表面生长因子8（MFGE8）、糖类抗原153（CA153）和癌胚抗原（CEA）在乳腺癌中的表达及其意义.方法 选取乳腺癌患者、乳腺纤维瘤患者和健康体检者各30例,采用酶联免疫吸附试验（ELISA）检测MFGE8水平,采用电化学发光法检测CA153、CEA水平.结果 乳腺癌患者血清中MFGE8、CA153、CEA分别为（6032.3±3043.7） ng/L、（58.72±28.80） U/ml、（4.35 ± 3.20） μg,/L,明显高于良性组和对照组,与两组间差异有统计学意义（P＜0.01）.MFGE8、CA153、CEA诊断乳腺癌的敏感性分别为68.4％、55.9％、33.5％,良性组分别为8.1％、5.7％、3.1％,对照组分别为1.1％、0.7％、0.3％,各组间两两比较,差异有统计学意义（P＜0.05）.三者联合检测的敏感性为86.3％；准确性分别为88.3％、63.3％、55.6％,三者联合检测为92.2％.结论 MFGE8、CA153、CEA联合检测可做为乳腺癌的预测指标.

Objective To discuss the expression and significance of milk fat globule epidermal growth factor 8 （MFGE8） and carbohydrate antigen 153 （CA153）,carcinoembryonic antigen （CEA） in breast cancer.Methods 30 patients with breast cancer,30 patients with mammary gland fibroma and 30 healthy volunteers were selected.Eenzyme-linked immunosorbent assay was used to detect serum level of MFGES,and electrochemiluminescence immunoassay to detect serum level of CA153 and CEA.Results The serum levels of MFGE8,CA153 and CEA in patients with breast cancer were （6032.3 ±3043.7） ng/L,（58.72 ± 28.8） U/ml and （4.35 ± 3.2） μg/L respectively,which were significantly higher than others （P ＜ 0.01 for all）.The positive rate of MFGES,CA153 and CEA in patients with breast cancer was 68.4％,55.9％ and 33.5％,that was 8.1％,5.7％ and 3.1％ in patients with mammary gland fibroma,and that was 1.1％,0.7％ and 0.3％ in control group,respectively.There was significant difference between each two groups （P ＜ 0.05）.By combined detection of MFGE8,CA153 and CEA,the positive rate of breast cancer could be greatly improved to 86.3％.The accuracy of MFGE8,CA153 and CEA in patients with breast cancer was 88.3％,63.3％ and 55.6％ respectively.By combined detection of MFGE8,CA153 and CEA,the positive rate of breast cancer could be greatly improved to 92.2％.Conclusion The combined detection of MFGE8,CA153 and CEA can be used as predictors of breast cancer.